Answers are grounded in this paper and cite their sources.
Background Neonatal Respiratory Distress Syndrome (RDS) remains a leading cause of neonatal morbidity and mortality worldwide, predominantly affecting preterm infants. While the “surfactant era” has revolutionised acute management, the macro-level epidemiological transition of RDS requires continuous evaluation. This study aims to analyse historical trends and project the incidence, prevalence, mortality, and disability-adjusted life years (DALYs) of RDS globally and in Iran up to 2050. Methods Using data from the Global Burden of Disease (GBD) Study 2021, age-standardised rates (ASR) for RDS were extracted for 204 countries from 1990 to 2021. Projections to 2050 were generated using the GBD forecasting framework, which integrates Socio-demographic Index (SDI) trajectories through a cohort-component model combined with Gaussian process regression and ARIMA-based extrapolation. Joinpoint regression was employed to calculate annual percentage changes (APC), with a minimum of 2 years between joinpoints, a maximum of 5 joinpoints, and significance tested via the Monte Carlo permutation method. Results Globally, the ASR of RDS mortality declined dramatically from 48.5 (95% UI: 42.1–55.2) per 100,000 live births in 1990 to 12.8 (95% UI: 10.6–15.0) in 2021 (APC: − 4.3%, 95% UI: − 4.7 to − 3.9), driven by the widespread use of antenatal corticosteroids and surfactant replacement. Conversely, the incidence ASR increased slightly from 115.4 (105.2–125.1) to 132.6 (120.5–144.2) (APC: +0.5%, 0.2–0.8), reflecting the increased survival of extremely preterm infants at the edge of viability. In Iran, mortality dropped even faster from 55.4 (48.2–62.1) to 12.8 (10.5–15.1) (APC: − 4.8%, − 5.2 to − 4.3), while incidence rose from 98.2 (88.5–108.4) to 125.4 (114.2–136.8) (APC: +0.8%, 0.4–1.2). Consequently, global RDS-related DALYs fell from 3850 (3400–4300) to 1520 (1300–1750) (APC: − 3.0%, − 3.4 to − 2.6), with the burden shifting predominantly from Years of Life Lost (YLL) to acute Years Lived with Disability (YLD). Projections to 2050 suggest near elimination of RDS mortality in high SDI regions, while global incidence is projected to plateau. Conclusion RDS has transitioned from a highly fatal neonatal disease to a highly manageable acute condition. However, the stable or rising incidence of RDS, particularly in middle-SDI countries like Iran, indicates that surviving the acute phase continues to contribute to the population at risk for chronic complications such as Bronchopulmonary Dysplasia (BPD). Future policies must focus on primary prevention of prematurity and optimisation of acute respiratory support to minimise long-term lung injury.
No takes yet. Share an insight, caveat, or question.
Saeidi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: